The Prevalence of MRSA Nasal Carriage in Preoperative Pediatric Orthopaedic Patients

J. J. Walrath, 1 W. L. Hennrikus, 2 C. Zalonis, 3 A. M. Dyer, 4 and J. E. Latorre 5

1Department of Emergency Medicine, Yale-New Haven Hospital, New Haven, CT, USA
2Department of Orthopaedics, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
3Department of Infectious Diseases, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
4Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA
5Penn State College of Medicine, Hershey, PA, USA

Correspondence should be addressed to W. L. Hennrikus; whl5k@hotmail.com

Received 12 February 2016; Revised 23 July 2016; Accepted 25 July 2016

Risk factors for MRSA colonization have been well described [21–23]. Acquisition of this organism is typically associated with particular settings such as health care institutions like hospitals and long-term care facilities [24–26]. Then there are certain patient groups like those with prolonged hospitalization, past antimicrobial use, indwelling catheters, decubitus ulcers, use of intravenous drugs, treatment with enteral feedings or dialysis, and postoperative surgical wounds [25–27]. SSI can be caused by endogenous transmission of Staphylococcus aureus from the nose and skin to the surgical site [28].

Many studies have looked into the prevalence of MRSA in adult patients; however, few studies have looked at pediatric orthopaedic surgical patients [29]. The purpose of this study is to determine the prevalence of MRSA nasal carriage in preoperative pediatric orthopaedic patients, to identify risk factors of SSI due to MRSA, and to determine if MRSA nasal carriage is a predictor of postoperative infection in these patients. We hypothesized that the prevalence rate and
risk factors in pediatric patients would be similar to those in adults. We also propose that MRSA nasal carriage would be predictive of postoperative infection in our pediatric population.

2. Materials and Methods

The study protocol was reviewed and approved by the Penn State College of Medicine Institutional Review Board (IRB). 699 consecutive patients under the age of 18 years, who underwent orthopaedic or spinal neurosurgery between April 2009 and March 2011, were retrospectively studied from the MRSA screening registry maintained by the Department of Infectious Disease at our institution.

As part of an ongoing hospital surveillance program, swabs of the anterior nares are performed on all patients admitted who do not have a known prior diagnosis of MRSA, except for those patients in the obstetrical wing. Nasal swabs are collected within 48 hours of admission and processed using the BD GeneOhm™ MRSA Assay (Becton Dickinson Diagnostics, San Diego, CA). This method allows for direct detection of MRSA from the nasal specimen. It has manufacturer-reported sensitivity of 93% and specificity of 96%. This PCR-based assay detects unique gene sequences for identification of both S. aureus (orfX) and methicillin resistance (SCCmec) [30, 31]. During the time of this study, the surgeon was not made aware of the MRSA screening result until after the surgery is performed. Therefore, no special interventions were performed preoperatively in patients with positive MRSA nasal screening.

Patient charts were reviewed for demographic information (age and gender), diagnosis, tobacco use, comorbidities (diabetes, immunodeficiency, and renal deficiency), corticosteroid use, location of residence prior to hospitalization, prior hospitalization, type of surgery, skin preparation, antibiotic prophylaxis, class of wound contamination, and surgical site infection as defined by NSQIP as an infection occurring within 30 days of an operation at the site of the procedure at the superficial, deep, or organ level [32]. The primary aim was to identify risk factors for MRSA colonization, SSI (as defined by NSQIP as an infection within 30 days of an operation), and SSI due to methicillin-resistant Staphylococcus aureus by using univariate analysis of various factors including gender, diagnosis, prior hospitalization, underlying disorder, tobacco use/exposure, and corticosteroid use. The secondary aims were (i) to determine the prevalence of preoperative nasal carriage of MRSA in our cohort of patients and (ii) to estimate the risk of S. aureus SSI.

Fisher’s exact test was used for the analysis of categorical variables. The Wilcoxon nonparametric test was used for mean comparisons. p values below 0.05 were considered to be statistically significant.

3. Results

A total of 699 patient charts were reviewed. The baseline characteristics of the patients are shown in Table 1. 55% of the patients were males and 45% were females. The average age of the patients was 9.54 years with a range of 0 to 18 years. Forty-four patients (6.29%) screened positive for MRSA by nasal swab on admission. Twenty-eight of 44 patients (63.6%) that screened positive for MRSA were male.

Univariate analyses were performed to assess the risk factors for MRSA colonization, SSI overall, and SSI with MRSA (Table 2). The study identified prior hospitalization, the diagnoses of myelomeningocele, cerebral palsy and Chiari malformation, and other infections as risk factors for MRSA colonization. Risk factors for SSI overall included the diagnoses of myelomeningocele, Chiari malformation, and renal disease, as well as corticosteroid use prior to surgery. Risk factors for SSI with MRSA were diagnoses of myelomeningocele and renal disease.

Postoperatively, nine of 44 (20.5%) patients that screened positive for MRSA had a subsequent surgical site infection compared to 10 of 655 (1.52%) patients that screened negative for nasal MRSA ($p$ value < 0.001). Eight patients that screened positive for MRSA and had a SSI with MRSA also had the diagnosis of myelomeningocele. Overall, 203 of 699 patients (29%) had myelomeningocele. Children with myelomeningocele were more likely to screen positive for MRSA. For example, 18 out of 203 (8.87%) patients with myelomeningocele screened positive for MRSA compared to only 5.9% who did not have myelomeningocele. Among myelomeningocele patients, those that screened positive for MRSA were more likely to develop a SSI than those who screened MRSA negative on admission (44.4% versus 2.2%, $p$ value < 0.001). Eight out of 203 (3.9%) of myelomeningocele patients had a SSI with MRSA. Among patients without myelomeningocele, none developed a surgical site infection and no difference was detected between MRSA screening groups.

In addition, 88.9% of the MRSA positive and SSI positive patients were previously hospitalized at least once compared to 74.3% of the MRSA positive and SSI negative patients and 51.3% of the MRSA negative patients. Approximately 55% of patients in the study population had been previously hospitalized. 91% of these patients were admitted from their homes, 3.3% were newborns, 0.6% came from a group home, and 4.9% were transferred from an outside hospital.

No patient with a MRSA + nasal swab and a subsequent MRSA SSI had received vancomycin as a preoperative antibiotic. Antibiotic prophylaxis in this group of patients included cephalozin, ceftriaxone, or nafcillin. Three patients with a MRSA + nasal swab and no subsequent SSI had received vancomycin as a preoperative antibiotic. Antibiotic prophylaxis in this group of patients also included ampicillin, cefazolin, clindamycin, gentamycin, nafcillin, and zosyn.

Skin preparation in the patients who demonstrated a MRSA + nasal swab and a subsequent MRSA SSI included bacitracin and betadine. Skin preparation in the patients who demonstrated a MRSA + nasal swab and no subsequent SSI had received vancomycin as a preoperative antibiotic. Antibiotic prophylaxis in this group of patients also included ampicillin, cefazolin, clindamycin, gentamycin, nafcillin, and zosyn.

Skin preparation in the patients who demonstrated a MRSA + nasal swab and a subsequent MRSA SSI included bacitracin and betadine. Skin preparation in the patients who demonstrated a MRSA + nasal swab and no subsequent SSI included bacitracin, bacitracin polymyxin B, betadine, chlorhexidine, and DuraPrep. SSI can decrease but cannot be prevented by adequate skin preparation [22].

All patients who were MRSA+ on admission and developed a surgical site infection were found to be growing MRSA bacteria. For those who had a SSI and were MRSA negative on admission, eight were positive for methicillin-sensitive...
Table 1: Characteristics of the 699 patients included in the study with special emphasis on patients who tested MRSA positive on admission.

|                        | MRSA+ | MRSA− | Total |
|-------------------------|-------|-------|-------|
|                         | SSI+, n (%) | SSI−, n (%) | SSI+, n (%) | SSI−, n (%) | n (%) |
| Age, mean (range)       | 5.55 (0–18) | 8.14 (0–17) | 6.67 (0–15) | 8.91 (0–18) | 9.54 (0–18) |
| Gender                  |       |       |       |       |       |
| Male                    | 7 (77.8) | 21 (60.0) | 6 (60.0) | 352 (54.6) | 386 (55.2) |
| Female                  | 2 (22.2) | 14 (40.0) | 4 (40.0) | 293 (45.4) | 313 (44.8) |
| Location prior to hospitalization |       |       |       |       |       |
| Home                    | 7 (77.28) | 29 (82.9) | 9 (90.0) | 593 (91.9) | 638 (91.3) |
| Newborn                 | 2 (22.2) | 3 (8.57) | 0 (0.0) | 18 (2.8) | 23 (3.3) |
| Group home              | 0 (0.0) | 1 (2.85) | 0 (0.0) | 3 (0.5) | 4 (0.6) |
| Other hospital          | 0 (0.0) | 2 (5.71) | 1 (10.0) | 31 (4.8) | 34 (4.9) |
| Prior hospitalization in last 5 years |       |       |       |       |       |
| Yes                     | 8 (88.9) | 26 (74.3) | 5 (50.0) | 331 (51.3) | 370 (52.9) |
| No                      | 1 (11.1) | 9 (25.7) | 5 (50.0) | 314 (48.7) | 329 (47.1) |
| Diagnosis*              |       |       |       |       |       |
| Myelomeningocele        | 8 (88.9) | 10 (28.6) | 4 (40.0) | 181 (28.1) | 203 (29.0) |
| Cerebral palsy          | 0 (0.0) | 3 (8.6) | 0 (0.0) | 34 (5.3) | 37 (5.3) |
| Trauma                  | 0 (0.0) | 6 (171) | 1 (10.0) | 149 (23.1) | 156 (22.3) |
| Tumor                   | 0 (0.0) | 2 (5.7) | 1 (10.0) | 52 (8.1) | 55 (7.9) |
| Infection               | 1 (11.1) | 7 (20.0) | 1 (10.0) | 34 (5.3) | 43 (6.2) |
| Scoliosis               | 0 (0.0) | 2 (5.71) | 0 (0.0) | 95 (14.7) | 97 (13.9) |
| Chiari malformation     | 2 (22.2) | 1 (2.85) | 2 (20.0) | 33 (5.1) | 38 (5.4) |
| Other                   | 1 (11.1) | 9 (25.7) | 3 (30.0) | 142 (22.0) | 154 (22.0) |
| Surgery                 |       |       |       |       |       |
| Neurosurgery            | 9 (100) | 20 (57.1) | 9 (90.0) | 359 (55.7) | 397 (56.8) |
| Orthopaedic surgery     | 0 (0.0) | 15 (42.9) | 1 (10.0) | 286 (44.3) | 302 (43.2) |
| Wound class             |       |       |       |       |       |
| Clean                   | 9 (100.0) | 24 (68.6) | 10 (100.0) | 590 (91.5) | 633 (90.6) |
| Clean–contaminated      | 0 (0.0) | 8 (22.9) | 0 (0.0) | 38 (5.9) | 46 (6.6) |
| Contaminated            | 0 (0.0) | 3 (8.6) | 0 (0.0) | 11 (1.7) | 14 (2.0) |
| Infected                | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.9) | 6 (0.9) |
| Underlying disorder     |       |       |       |       |       |
| Diabetes mellitus       | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (0.9) | 6 (0.9) |
| Immunocompromised       | 1 (11.1) | 2 (5.7) | 1 (10.0) | 24 (3.7) | 28 (4.0) |
| Renal disease           | 4 (44.4) | 0 (0.0) | 1 (10.0) | 39 (6.0) | 44 (6.8) |
| Tobacco use/exposure    |       |       |       |       |       |
| Yes                     | 0 (0.0) | 1 (2.9) | 0 (0.0) | 34 (5.3) | 35 (5.0) |
| No                      | 9 (100.0) | 34 (97.1) | 10 (100.0) | 611 (94.7) | 664 (95.0) |
| Corticosteroid use (%)  |       |       |       |       |       |
| Yes                     | 3 (33.3) | 6 (17.1) | 0 (0.0) | 52 (8.1) | 61 (8.7) |
| No                      | 6 (76.7) | 29 (82.9) | 10 (100.0) | 593 (91.9) | 638 (91.3) |

*Many individuals had multiple diagnoses and were thus counted twice.

S. aureus (MSSA), one for pseudomonas, and one for MRSA. Notably, the only patient who grew MRSA had multiple diagnoses of myelomeningocele, infection, and Chiari malformation.

4. Discussion

Decreasing SSI is a major focus in patient safety and quality programs. The increasing prevalence of community-acquired MRSA and current antibiotic-prescribing trends make MRSA a concern for the orthopaedic surgeon [33, 34]. No general consensus exists concerning the optimal preoperative decolonization and/or prophylaxis of patients who are colonized with MRSA [35–41]. However, identifying potential risk factors for MRSA acquisition in children may help prevent subsequent SSI.

There are several notable findings reported in the current study. The first finding is that the prevalence of nosocomial
Table 2: Univariate analysis of risk factors for MRSA colonization, SSI overall, and SSI due to MRSA.

| Risk factors                   | MRSA colonization p value | SSI overall p value | SSI due to MRSA p value |
|-------------------------------|---------------------------|--------------------|------------------------|
| Male gender versus female gender | 0.2                       | 1                  | 0.69                   |
| Prior hospitalization         | 0.001                     | 0.10               | 0.41                   |
| Diagnosis                     |                           |                    |                        |
| Myelomeningocele              | <0.001                    | <0.001             | <0.001                 |
| Cerebral palsy                | 0.035                     | 1                  | 1                      |
| Trauma                        | 0.33                      | 0.15               | 0.32                   |
| Tumor                         | 1                         | 1                  | 1                      |
| Infection                     | <0.001                    | 0.21               | 1                      |
| Scoliosis                     | 0.21                      | 0.15               | 1                      |
| Chiari malformation           | 0.043                     | <0.001             | 0.092                  |
| Other                         | 0.058                     | 0.60               | 0.32                   |
| Underlying disorder           |                           |                    |                        |
| Diabetes mellitus             | 1                         | 1                  | 1                      |
| Immune compromised            | 0.40                      | 0.17               | 0.49*                  |
| Renal disease                 | 0.51                      | 0.0098             | 0.003                  |
| Tobacco use/exposure          | 0.16                      | 0.41               | 1                      |
| Corticosteroid use            | 0.088                     | 0.001              | 0.61                   |

*One-tail test.

carriage of MRSA in our pediatric population was 6.29%. This pediatric prevalence rate is consistent with those found in adult populations on orthopaedic and surgical wards [6]. The second finding is that pediatric patients who were MRSA positive on the nasal screening before surgery were significantly more likely than patients who were MRSA negative on the preoperative nasal screening to have a postoperative SSI. All patients who were MRSA positive and developed a SSI were found to be growing MRSA and not another bacterium. This suggests a high likelihood of developing a SSI secondary to MRSA if one is MRSA positive on admission and supports the fact that nasal carriage of MRSA at the time of surgery is a risk factor for MRSA SSI [34–40]. In addition, patients who were MRSA negative and obtained a SSI were predominantly due to MSSA and not MRSA. This signifies that emphasis in screening for colonization of both MRSA and MSSA presurgically may be of benefit.

Furthermore, children with a diagnosis of renal failure or infection prior to surgery who were MRSA positive on admission were significantly more likely to develop a SSI than their MRSA negative counterparts. This has the potential of being important knowledge prior to pediatric surgeries to ensure that special measures can be taken with known MRSA carriers. Children with myelomeningocele were at the highest risk of being positive for MRSA on nasal PCR testing and for postoperative SSI with MRSA. This supports prior studies suggesting that patients with myelomeningocele are at the highest risk for SSI after posterior spinal fusion [42, 43]. In general, myelomeningocele has a higher risk of hospitalization, antibiotic use, and surgical exposure.

This study has a few limitations. For example, variations among populations in *S. aureus* carriage and infection by geographic location raise questions about the generalizability of these data from central Pennsylvania to other populations. Moreover, sampling was limited to the anterior nares. Although this site is considered the primary colonization site for MRSA, other sites including the throat, groin, axilla, and perianal areas can be colonized. Therefore, using a single nasal swab, the carriage frequency of MRSA in our cohort may be underestimated. The preoperative skin preparations were variable and not controlled. In addition, our institution uses the BD GeneOhm MRSA Assay as the standard screening protocol. No other enrichment media are typically used. This means that our sensitivity in ruling out MRSA was not as high as it could have been.

5. Conclusions

In conclusion, the optimization of perioperative methods to prevent infection is essential. In the current study, myelomeningocele, renal disease, and a current infection were significant risk factors on postoperative infection in MRSA positive patients. Future studies should target myelomeningocele patients for infection control and treatment as well as those who have an infection at the time of surgery and patients with renal failure.

Disclosure

This manuscript was presented in the POSNA annual meeting in 2013.

Competing Interests

The authors declare that there are no competing interests.
References

[1] M. J. Rybak and K. L. LaPlante, “Community-associated methicillin-resistant Staphylococcus aureus: a review,” Pharmacotherapy, vol. 25, no. 1, pp. 74–85, 2005.

[2] H. F. Chambers, “The changing epidemiology of staphylococcus aureus?” Emerging Infectious Diseases, vol. 7, no. 2, pp. 178–182, 2001.

[3] F. D. Lowy, “Staphylococcus aureus infections,” The New England Journal of Medicine, vol. 339, no. 8, pp. 520–532, 1998.

[4] A. L. Frank, J. F. Marcinak, P. D. Mangat, and P. C. Schreckenberger, “Increase in community-acquired methicillin-resistant Staphylococcus aureus in children,” Clinical Infectious Diseases, vol. 29, no. 4, pp. 935–936, 1999.

[5] M. P. Jevons, “‘Celbenin’-resistant Staphylococci,” British Medical Journal, vol. 1, no. 5219, pp. 124–125, 1961.

[6] A. Samad, D. Banerjee, N. Carbarns, and S. Ghosh, “Prevalence of methicillin-resistant Staphylococcus aureus colonization in surgical patients, on admission to a Welsh hospital,” Journal of Hospital Infection, vol. 51, no. 1, pp. 43–46, 2000.

[7] M. S. Barakate, Y.-X. Yang, S.-H. Foo et al., “An epidemiological survey of methicillin-resistant Staphylococcus aureus in a tertiary referral hospital,” The Journal of Hospital Infection, vol. 44, no. 1, pp. 19–26, 2000.

[8] A. J. Jernigan, M. A. Clemence, G. A. Stott et al., “Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later,” Infection Control and Hospital Epidemiology, vol. 16, no. 12, pp. 686–696, 1995.

[9] S. H. Cohen, M. M. Morita, and M. Bradford, “A seven-year experience with methicillin-resistant Staphylococcus aureus,” The American Journal of Medicine, vol. 91, no. 3, pp. S233–S237, 1991.

[10] NNIS System, “National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003,” American Journal of Infection Control, vol. 31, no. 8, pp. 481–498, 2003.

[11] W. C. Lye, S. O. Leong, and E. J. C. Lee, “Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD,” Kidney International, vol. 43, no. 6, pp. 1357–1362, 1993.

[12] R. R. Muder, C. Brennen, M. M. Wagener et al., “Methicillin-resistant staphylococcal colonization and infection in a long-term care facility,” Annals of Internal Medicine, vol. 114, no. 2, pp. 107–112, 1991.

[13] D. R. Mest, D. H. Wong, K. J. Shimoda, M. E. Mulligan, and S. E. Wilson, “Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection,” Anesthesia and Analgesia, vol. 78, no. 4, pp. 644–650, 1994.

[14] P. Berthelot, F. Grattard, C. Cazorla et al., “Is nasal carriage of Staphylococcus aureus the main acquisition pathway for surgical-site infection in orthopaedic surgery?” European Journal of Clinical Microbiology and Infectious Diseases, vol. 29, no. 4, pp. 373–382, 2010.

[15] T. G. Emori and R. P. Gaynes, “An overview of nosocomial infections, including the role of the microbiology laboratory,” Clinical Microbiology Reviews, vol. 6, no. 4, pp. 428–442, 1993.

[16] J. M. Boyce, G. Potter-Bynoe, and L. Dziobek, “Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery,” Infection Control and Hospital Epidemiology, vol. 11, no. 2, pp. 89–93, 1990.

[17] J. W. Green and R. P. Wenzel, “Postoperative wound infection: a controlled study of the increased duration of hospital stay and direct cost of hospitalization,” Annals of Surgery, vol. 185, no. 3, pp. 264–268, 1977.

[18] R. M. Nelson and D. J. Dries, “The economic implications of infection in cardiac surgery,” Annals of Thoracic Surgery, vol. 42, no. 3, pp. 240–246, 1986.

[19] K. B. Kirkland, J. P. Briggs, S. L. Trivette, W. E. Wilkinson, and D. J. Sexton, “The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs,” Infection Control and Hospital Epidemiology, vol. 20, no. 11, pp. 725–730, 1999.

[20] J. D. Whitehouse, N. D. Friedman, K. B. Kirkland, W. J. Richardson, and D. J. Sexton, “The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost,” Infection Control and Hospital Epidemiology, vol. 23, no. 4, pp. 183–189, 2002.

[21] C. S. Moucha, T. Clyburn, R. P. Evans, and L. Prokusi, “Modifiable risk factors for surgical site infection,” The Journal of Bone & Joint Surgery—American Volume, vol. 93, no. 4, pp. 398–404, 2011.

[22] The American Academy of Orthopaedic Surgeons Patient Safety Committee and R. P. Evans, “Surgical site infection prevention and control: an emerging paradigm,” The Journal of Bone & Joint Surgery, vol. 91, supplement 6, pp. 2–9, 2009.

[23] J. M. Boyce, “Methicillin-resistant Staphylococcus aureus: detection, epidemiology, and control measures,” Infectious Disease Clinics of North America, vol. 3, no. 4, pp. 901–913, 1989.

[24] D. P. Levine, R. D. Cushing, J. Jui, and W. J. Brown, “Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center,” Annals of Internal Medicine, vol. 97, no. 3, pp. 330–338, 1982.

[25] A. W. Karchmer, “Nosocomial bloodstream infections: organisms, risk factors, and implications,” Clinical Infectious Diseases, vol. 31, supplement 4, pp. S139–S143, 2000.

[26] E. M. Graffunder and R. A. Venezia, “Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 999–1005, 2002.

[27] T. P. Lodise Jr., P. S. McKinnon, and M. Rybak, “Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance,” Infection Control and Hospital Epidemiology, vol. 24, no. 9, pp. 655–661, 2003.

[28] M. D. Kalmeijer, “Nasal carriage of staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery,” Infection Control and Hospital Epidemiology, vol. 21, no. 5, pp. 319–323, 2000.

[29] S. A. Larkin and B. S. Murphy, “Preoperative decolonization of methicillin-resistant Staphylococcus aureus,” Orthopedics, vol. 31, no. 1, pp. 37–41, 2008.

[30] K. Oberdorfer, S. Pohl, M. Frey, K. Heeg, and C. Wendt, “Evaluation of a single-locus real-time polymerase chain reaction as a screening test for specific detection of methicillin-resistant Staphylococcus aureus in ICU patients,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 10, pp. 657–663, 2006.

[31] S. M. Paule, D. M. Hacek, B. Kufner et al., “Performance of the BD GeneOhm methicillin-resistant Staphylococcus aureus test before and during high-volume clinical use,” Journal of Clinical Microbiology, vol. 45, no. 9, pp. 2993–2998, 2007.

[32] American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), “Variable definitions,” in Advances in Orthopedics.
ACS NSQIP Operations Manual, pp.1–139, American College of Surgeons, Chicago, Ill, USA, 2013.

[33] I. Skrømm, A. E. Fossum Moen, A. Åroen, and G. Bukholm, “Surgical site infections in orthopaedic surgery demonstrate clones similar to those in orthopaedic Staphylococcus aureus nasal carriers,” The Journal of Bone & Joint Surgery—American Volume, vol. 96, no. 11, pp. 882–888, 2014.

[34] A. Patel, R. P. Calfee, M. Plante, S. A. Fischer, N. Arcand, and C. Born, “Methicillin-resistant Staphylococcus aureus in orthopaedic surgery,” The Journal of Bone & Joint Surgery—British Volume, vol. 90, no. 11, pp. 1401–1406, 2008.

[35] D. J. Anderson and K. S. Kaye, “Controlling antimicrobial resistance in the hospital,” Infectious Disease Clinics of North America, vol. 23, no. 4, pp. 847–864, 2009.

[36] L. G. M. Bode, J. A. J. W. Kluytmans, H. F. L. Wertheim et al., “Preventing surgical-site infections in nasal carriers of Staphylococcus aureus,” The New England Journal of Medicine, vol. 362, no. 1, pp. 9–17, 2010.

[37] R. Batra, B. S. Cooper, C. Whiteley, A. K. Patel, D. Wyncoll, and J. D. Edgeworth, “Efficacy and limitation of a chlorhexidine-Based decolonization strategy in preventing transmission of Methillin-Resistant staphylococcus aureus in an intensive care unit,” Clinical Infectious Diseases, vol. 50, no. 2, pp. 201–217, 2010.

[38] S. Harbarth, C. Fankhauser, J. Schrenzel et al., “Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients,” The Journal of the American Medical Association, vol. 299, no. 10, pp. 1149–1157, 2008.

[39] S. Ichikawa, M. Ishihara, T. Okazaki et al., “Prospective study of antibiotic protocols for managing surgical site infections in children,” Journal of Pediatric Surgery, vol. 42, no. 6, pp. 1002–1007, 2007.

[40] M. D. Kalmeijer, H. Coertjens, P. M. Van Nieuwland-Bollen et al., “Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study,” Clinical Infectious Diseases, vol. 35, no. 4, pp. 353–358, 2002.

[41] K. J. Popovich, B. Hota, R. Hayes, R. A. Weinstein, and M. K. Hayden, “Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit,” Infection Control and Hospital Epidemiology, vol. 30, no. 10, pp. 959–963, 2009.

[42] T. Hatlen, K. Song, D. Shurtleff, and S. Duguay, “Contributory factors to postoperative spinal fusion complications for children with myelomeningocele,” Spine, vol. 35, no. 13, pp. 1294–1299, 2010.

[43] B. A. Ramo, D. W. Roberts, D. Tuason et al., “Surgical site infections after posterior spinal fusion for neuromuscular scoliosis: a thirty year experience at a single institution,” The Journal of Bone & Joint Surgery—American Volume, vol. 96, no. 24, pp. 2038–2048, 2014.